ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Flurbiprofen

Also written as “flurbiprofen”, “Flurbiprofen tablet” and “Flurbiprofen 100 mg”.

Its studies are mostly in Pharyngitis · HIV Infections · Diabetes Mellitus, Type 2 · Anemia · Periodontitis, led by 7 companies.

Drug pageFlurbiprofen: every studyMany companies study it; this page follows only the 12 they lead. All 31 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Mar 1, 200712 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only40 open or runningphase 1since Mar 1, 2007Mar 1, 2007none ahead
Reckittits history only30 open or runningphase 3since Jan 13, 2010Jan 13, 2010none ahead
Bristol-Myers Squibbits history only10 open or runningphase 1since Aug 26, 2014Aug 26, 2014none ahead
Dexcel Pharma Technologies10 open or runningphase 2since Dec 27, 2009Dec 27, 2009none ahead
Idorsia Pharmaceuticalsits history only10 open or runningphase 1since Feb 15, 2022Feb 15, 2022none ahead
Institut de Recherches Internationales Servier (I.R.I.S.)its history only10 open or runningphase 1since Nov 14, 2025Nov 14, 2025none ahead
Teikoku Seiyakuits history only10 open or runningphase 1since Jan 19, 2025Jan 19, 2025none ahead

Also a collaborator on its studies: SocraMetrics and HWI pharma services.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Dexcel Pharma Technologies only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 27, 2009First study: phase 2 study in PeriodontitisFirst studyNCT01040286 · Israel

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
dexibuprofenruleaponia-laboratories-incphase 46
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44

Studies

The one study Dexcel Pharma Technologies leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01040286Periodontitis · Israel2Completed

How it is read

Names in the registry

  • “Flurbiprofen”, 7 entries
  • “flurbiprofen”, 2 entries
  • “Flurbiprofen tablet”, 1 entry
  • “Flurbiprofen 100 mg”, 1 entry
  • “omeprazole, caffeine, flurbiprofen, rosiglitazone”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.